Add like
Add dislike
Add to saved papers

Joint model imputation to estimate the treatment effect on long-term survival using auxiliary events.

Clinical trial duration may be a concern in clinical research, especially in cancer trials where the endpoint is overall survival. A surrogate endpoint can be used as an auxiliary variable to analyze the treatment effect earlier. At an early time point, the high number of censored observations can be compensated by the imputation of the unobserved deaths times. We propose to use predictions of the risk of death from a joint model for a recurrent event and a terminal event, which account for disease relapse information. Two imputation methods were compared: sampling from the estimated parametric distribution of the survival time and sampling using its nonparametric estimation. The treatment effect and its standard error were estimated via multiple imputations. The performances of the two methods were compared in terms of bias in the estimates, standard errors, and coverage probability. Both methods were then retrospectively applied to two randomized clinical trials studying the effect of adjuvant chemotherapy in breast cancer patients.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app